Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth George

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|June 21, 2016
How real-world data compensate for scarce evidence in HTAElisabeth George
The Lancet. Oncology|September 20, 2011
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancerFiona Rinaldi, Elisabeth George, Peter Clark
The Lancet. Oncology|March 4, 2015
NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancerRosemary Lovett, Elisabeth George, Amanda Adler
The Lancet. Oncology|April 11, 2012
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapyFiona Rinaldi, Elisabeth George, Amanda I Adler
The Lancet. Oncology|July 27, 2012
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimenAnwar Jilani, Elisabeth George, Amanda I Adler
The Lancet. Oncology|November 6, 2009
Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisalPanagiota Vrouchou, Prashanth Kandaswamy, Elisabeth George, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Utility values in National Institute for Health and Clinical Excellence (NICE) Technology AppraisalsJonathan C Tosh, Louise J Longworth, Elisabeth George
The Lancet. Oncology|May 21, 2011
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemiaWhitney Miller, Joanne Holden, Elisabeth George, et al.
The Lancet. Oncology|October 21, 2014
NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancerAhmed Elsada, Fiona Pearce, Elisabeth George, et al.
The Journal of Nursing Administration|January 15, 2021
Satisfaction and Technology Acceptance of Staff Regarding Use of Continuous Video Monitoring in Comparison With SittersAbigail Hebb, Michael Kistler, Elisabeth George, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|June 21, 2016
How real-world data compensate for scarce evidence in HTAElisabeth George
The Lancet. Oncology|September 20, 2011
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancerFiona Rinaldi, Elisabeth George, Peter Clark
The Lancet. Oncology|March 4, 2015
NICE guidance on sipuleucel-T for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancerRosemary Lovett, Elisabeth George, Amanda Adler
The Lancet. Oncology|April 11, 2012
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapyFiona Rinaldi, Elisabeth George, Amanda I Adler
The Lancet. Oncology|July 27, 2012
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimenAnwar Jilani, Elisabeth George, Amanda I Adler
The Lancet. Oncology|November 6, 2009
Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisalPanagiota Vrouchou, Prashanth Kandaswamy, Elisabeth George, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 8, 2011
Utility values in National Institute for Health and Clinical Excellence (NICE) Technology AppraisalsJonathan C Tosh, Louise J Longworth, Elisabeth George
The Lancet. Oncology|May 21, 2011
NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemiaWhitney Miller, Joanne Holden, Elisabeth George, et al.
The Lancet. Oncology|October 21, 2014
NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancerAhmed Elsada, Fiona Pearce, Elisabeth George, et al.
The Journal of Nursing Administration|January 15, 2021
Satisfaction and Technology Acceptance of Staff Regarding Use of Continuous Video Monitoring in Comparison With SittersAbigail Hebb, Michael Kistler, Elisabeth George, et al.
Pageof 4